JGC
CELGZ

J. Goldman & Co’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

J. Goldman & Co’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-40,000
Closed -$322K – 362
2013
Q3 		$322K Buy
+40,000
New +$308K 0.03% 242

Other funds holding CELGZ

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
FA
FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

J. Goldman & Co's CELGZ Position: Q4 2013 in Review

J. Goldman & Co sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2013, closing a stake of 40,000 shares — an estimated $322K sold.

J. Goldman & Co first reported a position in CELGZ in Q3 2013 and held it in 1 quarter. The position peaked at $322K in Q3 2013. 25 funds tracked by Wall St. Rank hold CELGZ as of Q4 2013.

  • J. Goldman & Co reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2013 after selling out during the quarter.
  • J. Goldman & Co sold 40,000 Celgene Corporation Contingent Value Rights shares in Q4 2013, an estimated $322K.
  • J. Goldman & Co first reported a position in Celgene Corporation Contingent Value Rights in Q3 2013 and held it in 1 quarter.
  • J. Goldman & Co's Celgene Corporation Contingent Value Rights position peaked at $322K in Q3 2013.
  • 25 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2013.

Based on J. Goldman & Co's 13F filing for Q4 2013, filed 14 Feb 2014.